Larimar Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $375.0M
- Price
- $3.76
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.16%
- Volume
- 2.1M
Quote data as of 6:08 AM ET
About
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Quick stats
Shares outstanding103.9M
Computed float61.7M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001374690
Websitehttps://www.larimartx.com
AI Summary
AI-generated10d agomajorbullishregulatoryLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp in Friedreich’s ataxia, following FDA confirmation that the current data package appears sufficient for submission and review.
Long-term open-label data showed that 100% of participants maintained skin frataxin (FXN) levels above 50% of healthy volunteer means at 1 year, while clinical outcome measures improved relative to a worsening natural history reference population.
The company expects to submit the remaining BLA modules in the second half of 2026, initiate dosing in a confirmatory Phase 3 study in Q3 2026, and is targeting a mid-2027 launch if approved.
Red flags
- Anaphylaxis occurred in 10/43 (23%) of study participants
- Accelerated approval relies on a novel surrogate endpoint (skin FXN) requiring confirmatory Phase 3 data
- 21 participants discontinued from the open-label study